Cooper Companies (COO) to Release Quarterly Earnings on Thursday

Cooper Companies (NASDAQ:COO) is expected to be issuing its Q1 2026 results after the market closes on Thursday, March 5th. Analysts expect Cooper Companies to post earnings of $1.03 per share and revenue of $1.0237 billion for the quarter. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 5:00 PM ET.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the prior year, the business posted $1.04 earnings per share. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, analysts expect Cooper Companies to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $83.37 on Wednesday. The stock has a market cap of $16.27 billion, a P/E ratio of 44.35, a P/E/G ratio of 2.40 and a beta of 1.02. The firm’s 50-day simple moving average is $82.28 and its 200 day simple moving average is $75.87. Cooper Companies has a fifty-two week low of $61.78 and a fifty-two week high of $91.76. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30.

Analyst Ratings Changes

COO has been the subject of several recent analyst reports. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a report on Friday, December 5th. Wells Fargo & Company boosted their price target on shares of Cooper Companies from $72.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, December 5th. Robert W. Baird raised their price objective on shares of Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. Weiss Ratings upgraded shares of Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. Finally, Wall Street Zen raised shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $90.77.

Insider Activity

In related news, Director Lawrence Erik Kurzius acquired 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was purchased at an average price of $82.50 per share, for a total transaction of $165,000.00. Following the transaction, the director directly owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. This trade represents a 34.62% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Maria Rivas purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $82.13 per share, for a total transaction of $82,130.00. Following the purchase, the director owned 11,141 shares in the company, valued at $915,010.33. This trade represents a 9.86% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 16,014 shares of company stock valued at $1,304,416. 2.08% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cooper Companies

Hedge funds and other institutional investors have recently bought and sold shares of the company. Cresset Asset Management LLC raised its stake in shares of Cooper Companies by 7.5% during the 3rd quarter. Cresset Asset Management LLC now owns 4,393 shares of the medical device company’s stock worth $301,000 after purchasing an additional 306 shares in the last quarter. Captrust Financial Advisors grew its holdings in Cooper Companies by 10.0% during the second quarter. Captrust Financial Advisors now owns 3,500 shares of the medical device company’s stock worth $249,000 after purchasing an additional 317 shares during the period. Snowden Capital Advisors LLC increased its position in Cooper Companies by 10.0% during the second quarter. Snowden Capital Advisors LLC now owns 4,088 shares of the medical device company’s stock worth $291,000 after buying an additional 373 shares during the last quarter. Public Employees Retirement System of Ohio raised its stake in Cooper Companies by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 62,229 shares of the medical device company’s stock valued at $4,266,000 after buying an additional 386 shares during the period. Finally, Arkadios Wealth Advisors increased its holdings in shares of Cooper Companies by 14.3% during the 4th quarter. Arkadios Wealth Advisors now owns 3,552 shares of the medical device company’s stock worth $291,000 after acquiring an additional 444 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.